Chinese (SSE) Life Sciences Industry Analysis
UpdatedFeb 03, 2023
DataAggregated Company Financials
Companies23
- 7D-2.9%
- 3M9.5%
- 1Y-4.9%
- YTD14.1%
Over the last 7 days, the Life Sciences industry has dropped 5.4%, driven by a pullback from WuXi AppTec of 4.4%. The industry has fallen 7.1% in the last year. As for the next few years, earnings are expected to grow by 16% per annum.
Industry Valuation and Performance
Has the Chinese Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 03 Feb 2023 | CN¥691.5b | CN¥86.6b | CN¥20.8b | 58.8x | 33.2x | 8x |
| Sun, 01 Jan 2023 | CN¥604.0b | CN¥86.6b | CN¥20.8b | 50.9x | 29x | 7x |
| Tue, 29 Nov 2022 | CN¥578.2b | CN¥86.6b | CN¥20.8b | 49.5x | 27.8x | 6.7x |
| Thu, 27 Oct 2022 | CN¥573.5b | CN¥79.5b | CN¥18.7b | 52.4x | 30.7x | 7.2x |
| Sat, 24 Sep 2022 | CN¥517.9b | CN¥77.8b | CN¥17.0b | 45.6x | 30.4x | 6.7x |
| Mon, 22 Aug 2022 | CN¥620.5b | CN¥73.4b | CN¥17.1b | 62.3x | 36.2x | 8.5x |
| Wed, 20 Jul 2022 | CN¥711.1b | CN¥69.0b | CN¥15.2b | 70.8x | 46.9x | 10.3x |
| Fri, 17 Jun 2022 | CN¥624.7b | CN¥69.0b | CN¥15.2b | 62.7x | 41.1x | 9.1x |
| Sun, 15 May 2022 | CN¥607.3b | CN¥68.5b | CN¥15.1b | 55.8x | 40.1x | 8.9x |
| Tue, 12 Apr 2022 | CN¥620.5b | CN¥62.7b | CN¥15.0b | 58.6x | 41.4x | 9.9x |
| Thu, 10 Mar 2022 | CN¥566.0b | CN¥60.9b | CN¥14.0b | 59.3x | 40.3x | 9.3x |
| Sat, 05 Feb 2022 | CN¥616.6b | CN¥57.5b | CN¥12.3b | 67.6x | 50.1x | 10.7x |
| Mon, 03 Jan 2022 | CN¥740.4b | CN¥57.5b | CN¥12.3b | 90.4x | 60.1x | 12.9x |
| Wed, 01 Dec 2021 | CN¥876.6b | CN¥56.9b | CN¥12.1b | 97.6x | 72.2x | 15.4x |
| Fri, 29 Oct 2021 | CN¥863.5b | CN¥55.1b | CN¥11.8b | 101.4x | 73.2x | 15.7x |
| Sun, 26 Sep 2021 | CN¥898.9b | CN¥55.1b | CN¥12.7b | 108.3x | 70.5x | 16.3x |
| Tue, 24 Aug 2021 | CN¥911.5b | CN¥55.1b | CN¥12.7b | 98.6x | 71.5x | 16.5x |
| Wed, 30 Jun 2021 | CN¥984.9b | CN¥53.4b | CN¥11.5b | 101x | 85.6x | 18.5x |
| Sat, 03 Apr 2021 | CN¥691.7b | CN¥44.9b | CN¥10.4b | 73.9x | 66.3x | 15.4x |
| Tue, 05 Jan 2021 | CN¥649.8b | CN¥39.5b | CN¥7.8b | 74.9x | 82.8x | 16.4x |
| Fri, 09 Oct 2020 | CN¥513.4b | CN¥36.6b | CN¥6.7b | 82.9x | 76.4x | 14x |
| Thu, 02 Jul 2020 | CN¥481.9b | CN¥34.2b | CN¥6.3b | 89.8x | 76.9x | 14.1x |
| Sun, 05 Apr 2020 | CN¥291.3b | CN¥32.3b | CN¥4.4b | 59.9x | 65.7x | 9x |
Price to Earnings Ratio
69x
Current Industry PE
- Investors are pessimistic on the Chinese Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 32.4x which is lower than its 3-year average PE of 63.5x.
- The 3-year average PS ratio of 12.8x is higher than the industry's current PS ratio of 7.8x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have grown 67% per year over the last three years.
- Revenues for these companies have grown 39% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the Chinese Healthcare industry?
| CN Market | 1.47% | |
| Healthcare | -0.031% | |
| Life Sciences | -2.88% | |
| Clinical Research and Equipment | -2.88% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 688238 Obio Technology (Shanghai) | CN¥24.32 | 5.3% +CN¥601.7m | n/a | PE202.9x | |
| 301230 PharmaResources (Shanghai) | CN¥67.58 | 10.2% +CN¥480.5m | n/a | PE72.5x | |
| 688222 HitGen | CN¥16.00 | 5.8% +CN¥352.6m | -15.3% | PE145.3x | |
| 688265 Shanghai Model Organisms Center | CN¥56.50 | 6.0% +CN¥251.0m | -5.9% | PE147.2x | |
| 300813 Zhejiang Tailin BioEngineeringLtd | CN¥45.79 | 4.5% +CN¥164.7m | 4.7% | PE55.7x |